All In Biotech

Drug Trial Radar · NCT01989572

Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery

A Randomized, Placebo-Controlled Phase III Trial of Yeast Derived GM-CSF Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With "No Evidence of Disease" After Complete Surgical Resection of "Locally Advanced" and/or Stage IV Melanoma

Last checked: Nov 19, 2026Latest source record: Jun 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 815 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

815

Actual

Start

Feb 23, 2000

Primary completion

Oct 8, 2012

Study completion Jan 31, 2013

Sponsor

Sponsor type
NIH
First posted
Nov 21, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
Double (participant, investigator)
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized phase III trial studies sargramostim or vaccine therapy alone to see how well they work compared to sargramostim and vaccine therapy together in preventing disease recurrence in patients with melanoma that has been removed by surgery. Sargramostim may stimulate the immune system in different ways and stop tumor cells from growing. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. It is not yet known whether yeast derived sargramostim and vaccine therapy are more effective alone or together in preventing recurrence of melanoma.

Conditions

  • Iris Melanoma
  • Medium/Large Size Posterior Uveal Melanoma
  • Mucosal Melanoma
  • Ocular Melanoma With Extraocular Extension
  • Recurrent Melanoma
  • Recurrent Uveal Melanoma
  • Small Size Posterior Uveal Melanoma
  • Stage IIA Cutaneous Melanoma AJCC v6 and v7
  • Stage IIA Uveal Melanoma AJCC v7
  • Stage IIB Cutaneous Melanoma AJCC v6 and v7
  • Stage IIB Uveal Melanoma AJCC v7
  • Stage IIC Cutaneous Melanoma AJCC v6 and v7
  • Stage IIIA Cutaneous Melanoma AJCC v7
  • Stage IIIA Uveal Melanoma AJCC v7
  • Stage IIIB Cutaneous Melanoma AJCC v7
  • Stage IIIB Uveal Melanoma AJCC v7
  • Stage IIIC Cutaneous Melanoma AJCC v7
  • Stage IIIC Uveal Melanoma AJCC v7
  • Stage IV Cutaneous Melanoma AJCC v6 and v7
  • Stage IV Uveal Melanoma AJCC v7

Interventions

  • Laboratory Biomarker AnalysisOther

    Correlative studies

  • PlaceboOther

    Given GM-CSF placebo SC

  • PlaceboOther

    Given peptide placebo SC

  • SargramostimBiological

    Given SC

  • Tyrosinase PeptideBiological

    Given SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: assessed every 3 months if patient is < 2 years from study entry and every 6 months if patient is 2-5 years from study entry, and annually if >5 years, up to year 15
  2. Recurrence Free SurvivalTime frame: assessed every 3 months if patient is < 2 years from study entry and every 6 months if patient is 2-5 years from study entry, and annually if >5 years, up to year 15

Locations

148 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama

  • Mobile Infirmary Medical Center

    Mobile, Alabama

  • Mayo Clinic in Arizona

    Scottsdale, Arizona

  • Banner University Medical Center - Tucson

    Tucson, Arizona

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • Alta Bates Summit Medical Center-Herrick Campus

    Berkeley, California

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • UC San Diego Moores Cancer Center

    La Jolla, California

  • Saint Joseph Hospital - Orange

    Orange, California

  • Stanford Cancer Institute Palo Alto

    Palo Alto, California

  • VA Palo Alto Health Care System

    Palo Alto, California

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California

  • Kaiser Permanente-San Diego Mission

    San Diego, California

  • Naval Medical Center -San Diego

    San Diego, California

  • Veterans Administration-San Diego Medical Center

    San Diego, California

  • The Medical Center of Aurora

    Aurora, Colorado

  • Boulder Community Hospital

    Boulder, Colorado

  • SCL Health Saint Joseph Hospital

    Denver, Colorado

  • Swedish Medical Center

    Englewood, Colorado

  • Saint Mary's Hospital and Regional Medical Center

    Grand Junction, Colorado

  • Manchester Memorial Hospital

    Manchester, Connecticut

  • Southwest Florida Regional Medical Center

    Fort Myers, Florida

  • Baptist MD Anderson Cancer Center

    Jacksonville, Florida

  • Mayo Clinic in Florida

    Jacksonville, Florida

  • Jupiter Medical Center

    Jupiter, Florida

  • Lakeland Regional Health Hollis Cancer Center

    Lakeland, Florida

  • Mount Sinai Medical Center

    Miami Beach, Florida

  • AdventHealth Orlando

    Orlando, Florida

  • Florida Cancer Specialists-West Palm Beach

    West Palm Beach, Florida

  • Cleveland Clinic-Weston

    Weston, Florida

  • Emory University Hospital/Winship Cancer Institute

    Atlanta, Georgia

  • Augusta University Medical Center

    Augusta, Georgia

  • Atlanta VA Medical Center

    Decatur, Georgia

  • Eisenhower Army Medical Center

    Fort Gordon, Georgia

  • Medical Center of Central Georgia

    Macon, Georgia

  • South Georgia Medical Center/Pearlman Cancer Center

    Valdosta, Georgia

  • Saint Luke's Mountain States Tumor Institute

    Boise, Idaho

  • Rush - Copley Medical Center

    Aurora, Illinois

  • Northwestern University

    Chicago, Illinois

  • University of Chicago Comprehensive Cancer Center

    Chicago, Illinois

Showing 40 of 148 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.